Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OKI-179+ binimetinib · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| OKI-179 + binimetinib | DRUG | Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously. Phase 2: Patients will be treated with the RP2D. |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Tango Therapeutics, Inc. | TNGX | 1 | PHASE1 | TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel |
| Pasithea Therapeutics Corp. | KTTA | 1 | PHASE1 | PAS-004 |
| Adlai Nortye Ltd. Sponsored ADR | ANL | 1 | PHASE1 | AN9025 |
| Myriad Genetics, Inc. | MYGN | 1 | PHASE1 | Melphalan, BCNU, Vitamin B12B, Vitamin C |
OKI-179 is an investigational small molecule being studied for the treatment of advanced solid tumors, including tumors with RAS mutations and NRAS-mutated melanoma. It is being developed by OnKure Therapeutics, Inc. (NASDAQ: OKUR) and is currently in clinical development, though it has not been approved by the FDA.
OKI-179 is a small molecule that targets the RAS pathway, which is involved in cell growth and division. By inhibiting this pathway, it aims to treat cancers driven by RAS mutations, including NRAS-mutated melanoma. The drug is being studied in combination with binimetinib in certain trials.
OKI-179 is being developed by OnKure Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol OKUR. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
OKI-179 is in Phase 1 clinical development. Two trials have been completed: a Phase 1 study in advanced solid tumors and a Phase 1/2 study in RAS pathway tumors and NRAS-mutated melanoma. The drug is investigational and has not received FDA approval.
OKI-179 has been studied in two completed clinical trials. NCT03931681 was a Phase 1 study in patients with advanced solid tumors, enrolling 34 participants. NCT05340621, called NAUTILUS, was a Phase 1/2 study of OKI-179 plus binimetinib in patients with RAS pathway tumors and NRAS-mutated melanoma, enrolling 36 participants.
OKI-179 is a distinct investigational drug and is not known to have alternative names. It is being studied alone and in combination with binimetinib, a MEK inhibitor, but it is not the same compound as binimetinib or any other approved therapy.